Inflammatory bowel disease: primary health care management of ulcerative colitis and Crohn's disease.
Inflammatory bowel disease encompasses both ulcerative colitis and Crohn's disease, two conditions so alike clinically that they are frequently indistinguishable from one another. Inflammatory bowel disease occurs at a rate of approximately five per 100,000 people. It tends to cluster in families and is seen four to five times more often in Jewish Caucasians than in other Caucasians. The etiology is unknown. Increasing attention is being paid to autoimmune factors, genetic factors and food allergies, and the notion that inflammatory bowel disease has its roots in a psychological disorder continues to pale for want of empirically sound evidence. Disease pattern is one of remission and exacerbation. The aim of therapy is to maintain an optimal lifestyle in remission through an individually tailored protocol of medications. Sulfasalazine remains the medication of choice; corticosteroids have short-term utility in exacerbation; and immunosuppressants, though controversial, are thought to have some steroid-sparing benefits during acute flare-ups. Indications for surgery vary, depending on whether or not a clear differential diagnosis has been made between ulcerative colitis and Crohn's disease. There is no cure for inflammatory bowel disease except for total colectomy in clearly diagnosed ulcerative colitis. Current research endeavors seek a cause or causes for inflammatory bowel disease, but the literature does not solidly support any one possibility above other rival etiologies.
Cooke
D M
DM
St. Louis University School of Nursing.
D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000451:nursing* / Q000628:therapy; D003424:Crohn Disease / Q000175:diagnosis / Q000451:nursing* / Q000628:therapy; D003937:Diagnosis, Differential; D004035:Diet Therapy; D004358:Drug Therapy; D006801:Humans; D009722:Nurse Practitioners; D011379:Prognosis